{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:50:46Z","timestamp":1790639446377,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:00:00Z","timestamp":1521158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2011-02352088"],"award-info":[{"award-number":["RF-2011-02352088"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2011-02351968"],"award-info":[{"award-number":["GR-2011-02351968"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2011-02352088"],"award-info":[{"award-number":["RF-2011-02352088"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005402","name":"Universita degli Studi di Bari Aldo Moro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005402","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Associazione Italiana Ricerca sul Cancro AIRC","award":["IG15696"],"award-info":[{"award-number":["IG15696"]}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["FIRB-Futuro in Ricerca RBFR12VP3Q_003"],"award-info":[{"award-number":["FIRB-Futuro in Ricerca RBFR12VP3Q_003"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurogenetics"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s10048-018-0540-1","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T02:06:01Z","timestamp":1521165961000},"page":"77-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)"],"prefix":"10.1007","volume":"19","author":[{"given":"C.","family":"Ranieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Di Tommaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. C.","family":"Loconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bagnulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. C.","family":"Susca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Peserico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Luisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bartuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Selicorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Melis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lerone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Pratic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Abbadessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2658-4249","authenticated-orcid":false,"given":"Martino","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Resta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,16]]},"reference":[{"issue":"7","key":"540_CR1","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/ajmg.a.36552","volume":"164A","author":"KM Keppler-Noreuil","year":"2014","unstructured":"Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VE, Blumhorst C, Darling T, Tosi LL, Huson SM, Whitehouse RW, Jakkula E, Grant I, Balasubramanian M, Chandler KE, Fraser JL, Gucev Z, Crow YJ, Brennan LM, Clark R, Sellars EA, Pena LD, Krishnamurty V, Shuen A, Braverman N, Cunningham ML, Sutton VR, Tasic V, Graham JM Jr, Geer J Jr, Henderson A, Semple RK, Biesecker LG (2014) Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A 164A(7):1713\u20131733. \nhttps:\/\/doi.org\/10.1002\/ajmg.a.36552","journal-title":"Am J Med Genet A"},{"issue":"2","key":"540_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ajmg.a.36836","volume":"167A","author":"KM Keppler-Noreuil","year":"2015","unstructured":"Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W, Biesecker LG (2015) PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A 167A(2):287\u2013295. \nhttps:\/\/doi.org\/10.1002\/ajmg.a.36836","journal-title":"Am J Med Genet A"},{"issue":"1","key":"540_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/JID.2015.331","volume":"136","author":"H Vahidnezhad","year":"2016","unstructured":"Vahidnezhad H, Youssefian L, Uitto J (2016) Molecular genetics of the PI3K-AKT-mTOR pathway in Genodermatoses: diagnostic implications and treatment opportunities. J Invest Dermatol 136(1):15\u201323. \nhttps:\/\/doi.org\/10.1038\/JID.2015.331","journal-title":"J Invest Dermatol"},{"issue":"4","key":"540_CR4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/bjd.14618","volume":"175","author":"H Vahidnezhad","year":"2016","unstructured":"Vahidnezhad H, Youssefian L, Baghdadi T, Sotoudeh S, Tavassoli A, Zeinali S, Afsharaalam S, Uitto J (2016) Phenotypic heterogeneity in PIK3CA-related overgrowth spectrum. Br J Dermatol 175(4):810\u2013814. \nhttps:\/\/doi.org\/10.1111\/bjd.14618","journal-title":"Br J Dermatol"},{"issue":"4","key":"540_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.spen.2015.11.001","volume":"22","author":"M Ruggieri","year":"2015","unstructured":"Ruggieri M, Pratic\u00f2 AD (2015) Mosaic neurocutaneous phenotypes. Semin Pediatr Neurol 22(4):207\u2013233. \nhttps:\/\/doi.org\/10.1016\/j.spen.2015.11.001","journal-title":"Semin Pediatr Neurol"},{"issue":"1","key":"540_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/cge.12832","volume":"91","author":"A Martinez-Lopez","year":"2017","unstructured":"Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I, Herrera-Garcia JD, Luque-Valenzuela M, Sanchez-Cano D, Lopez-Gutierrez JC, Ruiz-Villaverde R, Tercedor-Sanchez J (2017) CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS). Clin Genet 91(1):14\u201321. \nhttps:\/\/doi.org\/10.1111\/cge.12832","journal-title":"Clin Genet"},{"issue":"2","key":"540_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/modpathol.3880510","volume":"15","author":"RR Raju","year":"2002","unstructured":"Raju RR, Hart WR, Magnuson DK, Reid JR, Rogers DG (2002) Genital tract tumors in Proteus syndrome: report of a case of bilateral paraovarian endometrioid cystic tumors of borderline malignancy and review of the literature. Mod Pathol 15(2):172\u2013180. \nhttps:\/\/doi.org\/10.1038\/modpathol.3880510","journal-title":"Mod Pathol"},{"key":"540_CR8","first-page":"392576","volume":"2015","author":"L Vasquez","year":"2015","unstructured":"Vasquez L, Tello M, Maza I, Oscanoa M, Due\u00f1as M, Castro H, Latorre A (2015) Endometrioid Paraovarian borderline cystic tumor in an infant with Proteus syndrome. Case Rep Oncol Med 2015:392576","journal-title":"Case Rep Oncol Med"},{"issue":"1","key":"540_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ajhg.2012.10.021","volume":"92","author":"MS Orloff","year":"2013","unstructured":"Orloff MS, He X, Peterson C, Chen F, Chen JL, Mester JL, Eng C (2013) Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet 92(1):76\u201380. \nhttps:\/\/doi.org\/10.1016\/j.ajhg.2012.10.021","journal-title":"Am J Hum Genet"},{"issue":"4","key":"540_CR10","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jpeds.2014.12.069","volume":"166","author":"VL Luks","year":"2015","unstructured":"Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bov\u00e9e JV, Rialon KL, Guevara CJ, Alomari AI, Greene AK, Fishman SJ, Kozakewich HP, Maclellan RA, Mulliken JB, Rahbar R, Spencer SA, Trenor CC 3rd, Upton J, Zurakowski D, Perkins JA, Kirsh A, Bennett JT, Dobyns WB, Kurek KC, Warman ML, McCarroll SA, Murillo R (2015) Lymphatic and other vascular malformative\/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr 166(4):1048\u20131054. \nhttps:\/\/doi.org\/10.1016\/j.jpeds.2014.12.069","journal-title":"J Pediatr"},{"issue":"4","key":"540_CR11","doi-asserted-by":"publisher","first-page":"e0123092","DOI":"10.1371\/journal.pone.0123092","volume":"10","author":"DC Loconte","year":"2015","unstructured":"Loconte DC, Grossi V, Bozzao C, Forte G, Bagnulo R, Stella A, Lastella P, Cutrone M, Benedicenti F, Susca FC, Patruno M, Varvara D, Germani A, Chessa L, Laforgia N, Tenconi R, Simone C, Resta N (2015) Molecular and functional characterization of three different postzygotic mutations in PIK3CA-related overgrowth Spectrum (PROS) patients: effects on PI3K\/AKT\/mTOR signaling and sensitivity to PIK3 inhibitors. PLoS One 10(4):e0123092. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0123092","journal-title":"PLoS One"},{"issue":"8","key":"540_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/ng.2332","volume":"44","author":"MJ Lindhurst","year":"2012","unstructured":"Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, Witkowski AM, Zhang Q, Groeneveld MP, Scott CE, Daly A, Huson SM, Tosi LL, Cunningham ML, Darling TN, Geer J, Gucev Z, Sutton VR, Tziotzios C, Dixon AK, Helliwell T, O'Rahilly S, Savage DB, Wakelam MJ, Barroso I, Biesecker LG, Semple RK (2012) Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet 44(8):928\u2013933. \nhttps:\/\/doi.org\/10.1038\/ng.2332","journal-title":"Nat Genet"},{"key":"540_CR13","first-page":"287","volume":"167A","author":"T Takenouchi","year":"2015","unstructured":"Takenouchi T, Sakamoto Y, Torii C, Hata K, Kosaki R, Kosaki K (2015) Mosaic overgrowth with fibroadipose hyperplasia due to AKT1 mutation. Am J Med Genet A 167A:287\u2013295","journal-title":"Am J Med Genet A"},{"issue":"3","key":"540_CR14","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/hmg\/dds440","volume":"22","author":"JJ Rios","year":"2013","unstructured":"Rios JJ, Paria N, Burns DK, Israel BA, Cornelia R, Wise CA, Ezaki M (2013) Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. Hum Mol Genet 22(3):444\u2013451. \nhttps:\/\/doi.org\/10.1093\/hmg\/dds440","journal-title":"Hum Mol Genet"},{"issue":"1","key":"540_CR15","doi-asserted-by":"publisher","first-page":"12e","DOI":"10.1097\/01.prs.0000436822.26709.7c","volume":"133","author":"RA Maclellan","year":"2014","unstructured":"Maclellan RA, Luks VL, Vivero MP, Mulliken JB, Zurakowski D, Padwa BL, Warman ML, Greene AK, Kurek KC (2014) PIK3CA activating mutations in facial infiltrating lipomatosis. Plast Reconstr Surg 133(1):12e\u201319e. \nhttps:\/\/doi.org\/10.1097\/01.prs.0000436822.26709.7c","journal-title":"Plast Reconstr Surg"},{"issue":"5","key":"540_CR16","first-page":"5924","volume":"8","author":"S Tajima","year":"2015","unstructured":"Tajima S, Takanashi Y, Koda K (2015) Enlarging cystic lymphangioma of the mediastinum in an adult: is this a neoplastic lesion related to the recently discovered PIK3CA mutation? Int J Clin Exp Pathol 8(5):5924\u20135928","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"540_CR17","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/ajmg.a.38105","volume":"173","author":"KS Yeung","year":"2017","unstructured":"Yeung KS, Ip JJ, Chow CP, Kuong EY, Tam PK, Chan GC, Chung BH (2017) Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum. Am J Med Genet A 173(4):978\u2013984. \nhttps:\/\/doi.org\/10.1002\/ajmg.a.38105","journal-title":"Am J Med Genet A"},{"issue":"33","key":"540_CR18","doi-asserted-by":"publisher","first-page":"13450","DOI":"10.1073\/pnas.0705218104","volume":"104","author":"C Hafner","year":"2007","unstructured":"Hafner C, L\u00f3pez-Knowles E, Luis NM, Toll A, Baselga E, Fern\u00e1ndez-Casado A, Hern\u00e1ndez S, Rib\u00e9 A, Mentzel T, Stoehr R, Hofstaedter F, Landthaler M, Vogt T, Pujol RM, Hartmann A, Real FX (2007) Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A 104(33):13450\u201313454. \nhttps:\/\/doi.org\/10.1073\/pnas.0705218104","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"540_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1055\/s-0035-1564441","volume":"4","author":"MAM Steensel van","year":"2015","unstructured":"van Steensel MAM (2015) Neurocutaneous manifestations of genetic mosaicism. J Pediatr Genet 4(3):144\u2013153. \nhttps:\/\/doi.org\/10.1055\/s-0035-1564441","journal-title":"J Pediatr Genet"},{"issue":"6","key":"540_CR20","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.05.006","volume":"90","author":"KC Kurek","year":"2012","unstructured":"Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, Mulliken JB, Bowen ME, Yamamoto GL, Kozakewich HP, Warman ML (2012) Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet 90(6):1108\u20131115. \nhttps:\/\/doi.org\/10.1016\/j.ajhg.2012.05.006","journal-title":"Am J Hum Genet"},{"issue":"1","key":"540_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/exd.12826","volume":"25","author":"H Vahidnezhad","year":"2016","unstructured":"Vahidnezhad H, Youssefian L, Uitto J (2016) Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS). Exp Dermatol 25(1):17\u201319. \nhttps:\/\/doi.org\/10.1111\/exd.12826","journal-title":"Exp Dermatol"},{"issue":"8","key":"540_CR22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/ng.2331","volume":"44","author":"JB Rivi\u00e8re","year":"2012","unstructured":"Rivi\u00e8re JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrynbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GM, Meschino WS, Reggin JD, Saggar AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL, Finding of Rare Disease Genes (FORGE) Canada Consortium, Majewski J, Bulman DE, O'Driscoll M, Shendure J, Graham JM Jr, Boycott KM, Dobyns WB (2012) De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 44(8):934\u2013940. \nhttps:\/\/doi.org\/10.1038\/ng.2331","journal-title":"Nat Genet"},{"issue":"8","key":"540_CR23","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/ng.2329","volume":"44","author":"JH Lee","year":"2012","unstructured":"Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, Funari V, Russ C, Gabriel SB, Mathern GW, Gleeson JG (2012) De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 44(8):941\u2013945. \nhttps:\/\/doi.org\/10.1038\/ng.2329","journal-title":"Nat Genet"},{"issue":"6","key":"540_CR24","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/brain\/awv045","volume":"138","author":"LA Jansen","year":"2015","unstructured":"Jansen LA, Mirzaa GM, Ishak GE, O'Roak BJ, Hiatt JB, Roden WH, Gunter SA, Christian SL, Collins S, Adams C, Rivi\u00e8re J-B, St-Onge J, Ojemann JG, Shendure J, Hevner RF, Dobyns WB (2015) PI3K\/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. Brain 138(6):1613\u20131628. \nhttps:\/\/doi.org\/10.1093\/brain\/awv045","journal-title":"Brain"},{"issue":"6","key":"540_CR25","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ajhg.2015.11.011","volume":"97","author":"N Limaye","year":"2015","unstructured":"Limaye N, Kangas J, Mendola A, Godfraind C, Schl\u00f6gel MJ, Helaers R, Eklund L, Boon LM, Vikkula M (2015) Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet 97(6):914\u2013921. \nhttps:\/\/doi.org\/10.1016\/j.ajhg.2015.11.011","journal-title":"Am J Hum Genet"},{"issue":"7","key":"540_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1104017","volume":"365","author":"MJ Lindhurst","year":"2011","unstructured":"Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O'Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG (2011) A mosaic activating mutation in AKT1 associated with the Proteus syndrome. New Engl J Med 365(7):611\u2013619. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1104017","journal-title":"New Engl J Med"},{"issue":"6055","key":"540_CR27","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1126\/science.1210878","volume":"334","author":"K Hussain","year":"2011","unstructured":"Hussain K, Challis B, Rocha N, Payne F, Minic M, Thompson A, Daly A, Scott C, Harris J, Smillie BJ, Savage DB, Ramaswami U, De Lonlay P, O'Rahilly S, Barroso I, Semple RK (2011) An activating mutation of AKT2 and human hypoglycemia. Science 334(6055):474. \nhttps:\/\/doi.org\/10.1126\/science.1210878","journal-title":"Science"},{"issue":"1","key":"540_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neuron.2012.03.010","volume":"74","author":"A Poduri","year":"2012","unstructured":"Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, Barry BJ, Bourgeois BF, Riviello JJ, Barkovich AJ, Black PM, Ligon KL, Walsh CA (2012) Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 74(1):41\u201348. \nhttps:\/\/doi.org\/10.1016\/j.neuron.2012.03.010","journal-title":"Neuron"},{"issue":"4","key":"540_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/ng0897-333","volume":"16","author":"DJ Marsh","year":"1997","unstructured":"Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C (1997) Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 16(4):333\u2013334. \nhttps:\/\/doi.org\/10.1038\/ng0897-333","journal-title":"Nat Genet"},{"issue":"1","key":"540_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/ng0597-64","volume":"16","author":"D Liaw","year":"1997","unstructured":"Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16(1):64\u201367. \nhttps:\/\/doi.org\/10.1038\/ng0597-64","journal-title":"Nat Genet"},{"issue":"41","key":"540_CR31","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1038\/onc.2008.245","volume":"27","author":"TL Yuan","year":"2008","unstructured":"Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497\u20135510. \nhttps:\/\/doi.org\/10.1038\/onc.2008.245","journal-title":"Oncogene"},{"issue":"7","key":"540_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2(7):489\u2013501. \nhttps:\/\/doi.org\/10.1038\/nrc839","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"540_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathways in cancer. Nat Rev Drug Discov 8(8):627\u2013644. \nhttps:\/\/doi.org\/10.1038\/nrd2926","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"540_CR34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/sj.bjc.6602970","volume":"94","author":"B Karakas","year":"2006","unstructured":"Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94(4):455\u2013459. \nhttps:\/\/doi.org\/10.1038\/sj.bjc.6602970","journal-title":"Br J Cancer"},{"issue":"2","key":"540_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccr.2007.07.014","volume":"12","author":"J Brugge","year":"2007","unstructured":"Brugge J, Hung MC, Mills GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer Cell 12(2):104\u2013107. \nhttps:\/\/doi.org\/10.1016\/j.ccr.2007.07.014","journal-title":"Cancer Cell"},{"issue":"47","key":"540_CR36","doi-asserted-by":"publisher","first-page":"12260","DOI":"10.1021\/bi801683k","volume":"47","author":"KE Landgraf","year":"2008","unstructured":"Landgraf KE, Pilling C, Falke JJ (2008) Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry 47(47):12260\u201312269. \nhttps:\/\/doi.org\/10.1021\/bi801683k","journal-title":"Biochemistry"},{"issue":"5712","key":"540_CR37","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of AKT\/PKB by the rictor-mTOR complex. Science 307(5712):1098\u20131101. \nhttps:\/\/doi.org\/10.1126\/science.1106148","journal-title":"Science"},{"issue":"2","key":"540_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1042\/BJ20121287","volume":"448","author":"A Najafov","year":"2012","unstructured":"Najafov A, Shpiro N, Alessi DR (2012) AKT is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors. Biochem J 448(2):285\u2013295. \nhttps:\/\/doi.org\/10.1042\/BJ20121287","journal-title":"Biochem J"},{"issue":"7","key":"540_CR39","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"BD Manning","year":"2007","unstructured":"Manning BD, Cantley LC (2007) AKT\/PKB signaling: navigating downstream. Cell 129(7):1261\u20131274. \nhttps:\/\/doi.org\/10.1016\/j.cell.2007.06.009","journal-title":"Cell"},{"key":"540_CR40","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3892\/ijo.2015.3306","volume":"8","author":"GM Nitulescu","year":"2016","unstructured":"Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, Fenga C, Spandidos D\u0391, Libra M, Tsatsakis AM (2016) Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use. Int J Oncol 8:869\u2013885","journal-title":"Int J Oncol"},{"key":"540_CR41","doi-asserted-by":"publisher","first-page":"e12703","DOI":"10.7554\/eLife.12703","volume":"4","author":"A Roy","year":"2015","unstructured":"Roy A, Skibo J, Kalume F, Ni J, Rankin S, Lu Y, Dobyns WB, Mills GB, Zhao JJ, Baker SJ, Millen KJ (2015) Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. elife 4:e12703","journal-title":"elife"},{"issue":"10","key":"540_CR42","doi-asserted-by":"publisher","first-page":"e0140479","DOI":"10.1371\/journal.pone.0140479","volume":"10","author":"Y Yu","year":"2015","unstructured":"Yu Y, Savage RE, Eathiraj S, Meade J, Wick MJ, Hall T, Abbadessa G, Schwartz B (2015) Targeting AKT1-E17K and the PI3K\/AKT pathway with an allosteric AKT inhibitor, ARQ 092. PLoS One 10(10):e0140479. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0140479","journal-title":"PLoS One"},{"key":"540_CR43","doi-asserted-by":"publisher","unstructured":"Wang Q, Chen X, Hay N (2017) Akt as a target for cancer therapy: more is not always better (lessons from studies in mice). Br J Cancer 19:63 doi: \nhttps:\/\/doi.org\/10.1186\/s13058-017-0854-1","DOI":"10.1186\/s13058-017-0854-1"},{"issue":"1","key":"540_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15(1):7\u201324. \nhttps:\/\/doi.org\/10.1038\/nrc3860","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"540_CR45","doi-asserted-by":"publisher","first-page":"17162","DOI":"10.1038\/srep17162","volume":"5","author":"MJ Lindhurst","year":"2015","unstructured":"Lindhurst MJ, Yourick MR, Yu Y, Savage RE, Ferrari D, Biesecker LG (2015) Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome. Sci Rep 5(1):17162. \nhttps:\/\/doi.org\/10.1038\/srep17162","journal-title":"Sci Rep"},{"issue":"2","key":"540_CR46","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd4204","volume":"13","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13(2):140\u2013156. \nhttps:\/\/doi.org\/10.1038\/nrd4204","journal-title":"Nat Rev Drug Discov"}],"container-title":["neurogenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10048-018-0540-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-018-0540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-018-0540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T04:05:47Z","timestamp":1574395547000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10048-018-0540-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,16]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1007\/s10048-018-0540-1","relation":{},"ISSN":["1364-6745","1364-6753"],"issn-type":[{"value":"1364-6745","type":"print"},{"value":"1364-6753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,16]]},"assertion":[{"value":"21 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"\u115f","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"All patients (and\/or their guardians) signed (or had previously signed [patients nos. 5 and 6 in reference<!--Citation<!--Too long, content removed-->"}},{"value":"D. C. Loconte, V. Grossi, S. Di Tommaso, C. Ranieri, P. Sanese, R. Bagnulo, G. Forte, F.C. Susca, A. Peserico, A. De Luisi, A. Bartuli, A. Selicorni, D. Melis, M.Lerone, A.D. Pratic\u00f2, M. Ruggieri, C. Simone, N. Resta declare that no competing interest exist. G. Abbadessa and Y. Yu are employees of ArQule, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients (and\/or their guardians) signed an informed consent approved by the local Ethics Committee at the \u201cAzienda Ospedaliero-Universitaria Consorziale Policlinico di Bari\u201d \u201cAldo Moro\u201d to participate in this study and to authorize the publication of clinical images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}